infliximab: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by dreye

infliximab Introduction (What it is)

infliximab is a prescription biologic medication that reduces inflammation by targeting a specific immune signal called tumor necrosis factor alpha (TNF-α).
It is given by intravenous (IV) infusion, meaning it is delivered into a vein over a set period of time.
It is commonly used in immune-mediated inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
In eye care, it may be used for certain severe or vision-threatening inflammatory eye conditions, often in coordination with other specialties.

Why infliximab used (Purpose / benefits)

Inflammation is a normal immune response, but in some conditions the immune system becomes overactive and attacks the body’s own tissues. In the eye, uncontrolled inflammation can affect delicate structures such as the uvea (the middle layer of the eye that includes the iris, ciliary body, and choroid), the retina (light-sensing tissue), and the optic nerve (the “cable” that transmits visual information to the brain). This can lead to pain, light sensitivity, floaters, blurry vision, and—when persistent—scarring or permanent vision loss.

infliximab is used to dampen an overactive inflammatory response when clinicians want stronger, longer-term control than local treatments alone (such as eye drops) can provide. In ophthalmology, the main goal is often to reduce inflammation quickly enough to prevent structural damage and preserve vision, while also lowering reliance on long-term systemic corticosteroids (steroids), which can have significant side effects.

Potential benefits—depending on the diagnosis, severity, and individual response—can include:

Better control of recurrent or severe ocular inflammation
Reduction in flare frequency (episodes of worsening inflammation)
Preservation of retinal and optic nerve function by limiting inflammatory injury
Support for tapering systemic steroid exposure when appropriate (varies by clinician and case)
Treatment of eye inflammation occurring as part of a broader systemic inflammatory disease

Indications (When ophthalmologists or optometrists use it)

Common eye-related scenarios where infliximab may be considered include:

Noninfectious uveitis, especially when severe, recurrent, or involving the posterior segment (back of the eye)
Behçet disease–associated uveitis, which can be aggressive and vision-threatening
Scleritis (inflammation of the sclera, the “white of the eye”) that is severe or resistant to first-line therapies
Retinal vasculitis (inflammation of retinal blood vessels) in selected noninfectious cases
Inflammatory chorioretinal disease affecting the choroid/retina in selected situations
Eye inflammation associated with systemic inflammatory diseases (for example, some forms of arthritis or inflammatory bowel disease), when systemic control is part of the treatment plan
Situations where clinicians are trying to reduce long-term systemic steroid use due to side-effect concerns (varies by clinician and case)

Contraindications / when it’s NOT ideal

infliximab is not appropriate for every patient or every type of eye inflammation. Whether it is suitable depends on the underlying diagnosis, infection risk, other medical conditions, and prior treatments.

Situations where infliximab is often avoided or used with extra caution include:

Active infections, especially serious or uncontrolled infections
Untreated latent tuberculosis (TB) or high TB risk without appropriate evaluation (screening practices vary by region and clinician)
Hepatitis B infection without appropriate assessment/monitoring, due to potential reactivation risk
Moderate to severe heart failure, where TNF-α inhibitors may be problematic (risk assessment varies by clinician and case)
History of demyelinating disease (conditions affecting nerve insulation, such as multiple sclerosis), where TNF-α inhibitors may not be preferred
Known hypersensitivity or prior severe infusion reaction to infliximab or formulation components
Suspected infectious uveitis (eye inflammation caused by infection), where suppressing immunity can worsen the underlying cause
Milder, localized eye inflammation that is well controlled with local therapy (e.g., topical drops or targeted injections), where systemic biologic therapy may be more treatment than needed

Because infliximab affects the immune system, clinicians also weigh factors such as prior malignancy history, vaccination status, planned surgeries, pregnancy considerations, and concurrent immunosuppressive medications. Specific decisions vary by clinician and case.

How it works (Mechanism / physiology)

Mechanism of action (high level)

infliximab is a monoclonal antibody that binds to TNF-α, a key signaling protein (cytokine) involved in inflammation. By neutralizing TNF-α, infliximab reduces downstream inflammatory signaling that can drive tissue swelling, immune-cell recruitment, and inflammatory damage.

It is sometimes described as a TNF inhibitor or anti–TNF-α therapy. Unlike steroid eye drops that act locally, infliximab is a systemic therapy that can affect inflammatory activity throughout the body, including the eyes.

Relevant eye anatomy and tissues

Inflammatory eye diseases may involve:

The uvea (iris, ciliary body, choroid), leading to anterior uveitis, intermediate uveitis, posterior uveitis, or panuveitis
The retina and retinal vessels, where inflammation can contribute to macular edema (fluid in the central retina) or vasculitis
The optic nerve, where inflammation can threaten central vision and visual fields
The sclera, where deeper inflammation can be painful and potentially vision-threatening

By reducing systemic inflammatory signaling, infliximab may help stabilize inflammatory activity that otherwise damages these structures.

Onset, duration, and reversibility

Onset: Many immune-modulating therapies do not work instantly. With infliximab, clinical response may occur over weeks, although timing varies widely by disease and individual factors.
Duration: Effects generally persist according to the infusion schedule and drug levels in the body. If infusions are stopped, the effect typically wanes over time.
Reversibility: It is not a permanent “cure.” Inflammation may return if the underlying disease remains active. Some patients develop anti-drug antibodies (immunogenicity), which can reduce effectiveness or increase infusion reactions; prevention and management strategies vary by clinician and case.

infliximab Procedure overview (How it’s applied)

infliximab is a medication, not an eye procedure. In eye-related use, it is typically part of a coordinated care plan involving ophthalmology and another specialty such as rheumatology, gastroenterology, or internal medicine.

A simplified, high-level workflow often looks like this:

Evaluation / exam – Detailed eye examination to document inflammation activity and affected structures – Baseline testing may include retinal imaging (such as OCT for macular edema) and photographs or angiography when indicated – Review of systemic medical history, current medications, and infection risk factors
Preparation – Pre-treatment screening practices vary, but often include evaluation for infections that can reactivate with immunosuppression (for example TB or hepatitis) – Review of vaccines and timing considerations may occur (specific recommendations vary by clinician and case) – Discussion of infusion logistics, monitoring plan, and warning symptoms to report
Intervention / administration – infliximab is given by IV infusion in a monitored setting (often an infusion center) – Infusion timing and dosing schedules depend on diagnosis, body weight–based protocols, and clinician preference (varies by clinician and case)
Immediate checks – Monitoring during and after the infusion for infusion reactions (such as rash, itching, chest tightness, shortness of breath, or blood pressure changes) – Documentation of any symptoms and response
Follow-up – Regular eye follow-up to measure inflammation control and detect complications (for example cataract, glaucoma related to steroid use, or macular edema) – Periodic laboratory monitoring may be used depending on comorbidities and combination therapy – Ongoing reassessment of benefit versus risk, including infection surveillance

Types / variations

Although “infliximab” is one medication, clinically relevant variations include the product type and how it is used within an overall inflammatory disease strategy.

Common variations include:

Originator infliximab vs biosimilars
There is an originator product and multiple biosimilar versions in many regions.
Biosimilars are designed to be highly similar in clinical effect, but they are not identical in manufacturing. Practical differences (such as formulary coverage, infusion protocols, or device packaging) vary by region and health system.
Induction and maintenance scheduling
Some regimens use an initial “loading” phase followed by maintenance infusions at regular intervals.
Interval and dose adjustments may be made based on response, side effects, and relapse patterns (varies by clinician and case).
Monotherapy vs combination therapy
infliximab may be used alone or combined with another immunomodulatory drug (for example, an antimetabolite) to improve durability of response and reduce antibody formation in some settings (varies by clinician and case).
On-label vs off-label eye use
Many ophthalmic uses involve off-label decision-making depending on the country and specific diagnosis. Clinicians base these decisions on disease severity, evidence base, and individual risk.
Therapeutic drug monitoring (selected cases)
In some specialties, drug levels and anti-drug antibodies may be measured to help explain loss of response or guide adjustments. Use varies by clinician and case.

Pros and cons

Pros:

Targets a specific inflammatory pathway (TNF-α) rather than broad, non-specific immunosuppression
Can be helpful for severe or refractory noninfectious ocular inflammation in selected patients
May reduce the frequency or intensity of inflammatory flares when effective
Systemic therapy can address eye and non-eye inflammation together when part of a systemic disease
IV infusion ensures medication delivery is supervised and documented
May allow reduction of long-term systemic steroid exposure in some treatment plans (varies by clinician and case)

Cons:

Suppresses immune function and can increase susceptibility to infections or infection reactivation risks
Requires infusion visits, monitoring time, and coordination with an infusion facility
Potential for infusion reactions ranging from mild to severe
Effectiveness can diminish if anti-drug antibodies develop (immunogenicity)
Not appropriate for infectious causes of eye inflammation
Cost and insurance coverage can be complex; access varies by region and plan
Requires ongoing monitoring for systemic side effects and complications (monitoring approach varies by clinician and case)

Aftercare & longevity

Because infliximab is used for inflammatory disease control rather than a one-time fix, “aftercare” mostly means consistent monitoring, symptom tracking, and follow-up testing.

Factors that commonly affect outcomes and durability include:

Underlying diagnosis and severity: Some conditions are more aggressive or relapse-prone than others.
How early inflammation is controlled: Prolonged uncontrolled inflammation can cause scarring that may not fully reverse even after inflammation improves.
Adherence to scheduled infusions: Delays can allow inflammation to return; real-world schedules may be affected by illness, logistics, or insurance coverage.
Ocular complications and comorbidities: Macular edema, cataract, glaucoma, or retinal scarring can influence vision outcomes independent of inflammation control.
Concurrent medications: Combination immunosuppression can change effectiveness and risk profile (varies by clinician and case).
Infection exposure and general health: Intercurrent infections may interrupt therapy and can mimic or worsen inflammatory symptoms.
Regular ophthalmic monitoring: Imaging (like OCT) and exams help distinguish active inflammation from permanent structural change.

Longevity of benefit varies. Some people maintain control on a stable schedule for extended periods, while others require adjustments due to incomplete response, side effects, or antibody development.

Alternatives / comparisons

The best comparison depends on what problem is being treated: acute flare control, long-term suppression, local eye-only disease, or systemic disease with eye involvement.

Common alternatives or complementary approaches include:

Observation / monitoring
For mild, self-limited, or clearly improving inflammation, clinicians may monitor closely rather than escalate to systemic therapy.
This approach depends heavily on location of inflammation and risk to vision.
Corticosteroids (local or systemic)
Topical steroid eye drops are often used for anterior segment inflammation.
Periocular or intraocular steroid injections can target posterior inflammation or macular edema in selected cases.
Oral or IV systemic steroids may rapidly reduce inflammation but can be limited by side effects with long-term use.
Conventional immunomodulatory therapy (non-biologic)
Medications such as methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, or tacrolimus are commonly used for steroid-sparing control in noninfectious uveitis.
They are often taken orally (or sometimes by injection) and require lab monitoring; onset can be gradual.
Other biologics
adalimumab (another TNF inhibitor) is commonly discussed in noninfectious uveitis treatment frameworks and is administered by injection rather than infusion.
Other targeted biologics (for example agents affecting IL-6, B cells, or other pathways) may be considered in selected refractory cases. Choice varies by clinician and case.
Local steroid implants or sustained-delivery options
Some patients may be candidates for long-acting intraocular steroid delivery, balancing local effectiveness with risks such as cataract and elevated eye pressure.

Compared with local therapies, infliximab is a systemic option that may be favored when inflammation is severe, posterior, bilateral, recurrent, or tied to systemic disease activity. Compared with oral immunosuppressants, infliximab is more targeted to TNF-α but still requires careful infection risk assessment and monitoring.

infliximab Common questions (FAQ)

Q: Is infliximab an eye drop or an eye injection?
infliximab is not an eye drop. It is typically given as an intravenous (IV) infusion, meaning it is delivered into a vein in a monitored setting. Eye care teams may use it as part of treatment for certain inflammatory eye diseases.

Q: Does infliximab treat “dry eye” or blurry vision from needing glasses?
No. infliximab is used for immune-mediated inflammation, not for refractive error (needing glasses/contacts) or typical dry eye disease. If vision is blurry, clinicians usually determine whether it is due to inflammation, macular swelling, cataract, ocular surface problems, or refractive issues.

Q: How quickly does infliximab start working for eye inflammation?
Timing varies by disease, severity, and individual response. Some people notice improvement over weeks, while others require more time or adjustments. Eye exams and imaging are often used to confirm whether inflammation is truly improving.

Q: Is infliximab considered “chemotherapy”?
It is not classic chemotherapy used for cancer treatment, though it does modify immune function. It is classified as a biologic immunomodulatory medication (a TNF inhibitor). The goals and monitoring differ from oncology chemotherapy, even though both can affect the immune system.

Q: Is infliximab painful to receive?
The medication is delivered through an IV line, so discomfort is usually related to starting the IV and sitting through the infusion. Some people have little discomfort, while others find the process inconvenient. Infusion experiences vary by individual and infusion center protocols.

Q: How long do the effects last?
Its effect typically relates to the infusion schedule and how your body processes the drug. If infusions are delayed or stopped, inflammation control may fade over time. Long-term durability depends on the underlying condition and whether anti-drug antibodies develop (varies by clinician and case).

Q: What are the main safety concerns people discuss with infliximab?
A major concern is infection risk, including reactivation of certain latent infections. Infusion reactions and immune-related side effects can also occur. Clinicians balance these risks against the risk of vision loss or systemic disease complications from uncontrolled inflammation.

Q: Can I drive or use screens after an infusion?
Many people can resume routine activities after an infusion, but this varies with fatigue, how the infusion went, and whether any premedications were used (which can cause drowsiness in some settings). Vision limitations are more often related to the underlying eye inflammation than to the infusion itself. Activity guidance is individualized by the treating team.

Q: Is infliximab expensive?
It can be costly, and out-of-pocket costs vary widely depending on insurance coverage, region, infusion site billing, and whether a biosimilar is used. Financial counseling through clinics or infusion centers may be part of the process, depending on the health system.

Q: Will I still need other eye treatments if I’m on infliximab?
Sometimes, yes. People with uveitis or related conditions may still use topical drops, pressure-lowering medications, or receive local steroid treatment depending on which eye structures are affected. The treatment plan often changes over time as inflammation activity changes.